vimarsana.com

Page 215 - பல்கலைக்கழகம் ஆஃப் சவுத்தாம்ப்டன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Altus Strategies PLC: Strategic Review of Bikoula Iron Project, Southern Cameroon

Altus Strategies PLC: Strategic Review of Bikoula Iron Project, Southern Cameroon Strategic Review ) by independent consultants Mining Plus UK Ltd ( Mining Plus ), on the Company s 97% owned high-grade Bikoula iron ( Fe ) project ( Bikoula or the Project ) located in southern Cameroon. The Strategic Review will be used to determine the next steps for the development of the Project. Highlights: Processing, product specification, development and shipment options reviewed Historical drilling includes 30.8m at 57.9% Fe from 3.8 m (potential true width of interval) Bikoula hosts a deposit with a historic independent JORC compliant Mineral Resource Estimate of 46 million tonnes at 44% Fe At least 75% of the 13 km long priority target area remains untested

After vaccine freeze, European countries seek a quick thaw

After vaccine freeze, European countries seek a quick thaw ANGELA CHARLTON and LORNE COOK, Associated Press March 17, 2021 FacebookTwitterEmail 17 1of17A woman pick up a vial of AstraZeneca vaccine from the box Tuesday from a fridge while a box Monday is seen at left, in a vaccination center in Saint-Jean-de-Luz, southwestern France, Tuesday, March 16, 2021. With coronavirus cases rising in many places, governments faced the grimmest of dilemmas Tuesday: push on with a vaccine that is known to save lives or suspend use of AstraZeneca over reports of dangerous blood clots in a few recipients, even as the European regulator said there was no indication the shot was responsible.Bob Edme/APShow MoreShow Less

No indication AstraZeneca shot causes clots, EU agency says

No indication AstraZeneca shot causes clots, EU agency says CNN 4 days ago © Reuters CDC releases illustration of the Coronavirus. After virtually all of western Europe temporarily suspended the use of Oxford-AstraZeneca s Covid-19 vaccine, the continent s top medicines regulator struck out against safety concerns around the shot, saying there is no indication that it causes blood clots and that its lifesaving benefits outweigh the risk of any potential side effects. The backing from Emer Cooke, executive director of the European Medicines Agency, came after France, Spain, Germany, Italy and more than a dozen other countries halted use of the vaccine, even as the continent confronts a third wave of the pandemic and faces criticism over sluggish vaccination rollout campaigns.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.